Imad Shureiqi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8148238/publications.pdf

Version: 2024-02-01

36	1,804	411340	406436
papers	citations	20 h-index	35 g-index

38	38	38	3097
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis. Cancer Prevention Research, 2022, 15, 217-223.	0.7	3
2	Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. International Journal of Molecular Sciences, 2022, 23, 1645.	1.8	4
3	BMP feed-forward loop promotes terminal differentiation in gastric glands and is interrupted by H. pylori-driven inflammation. Nature Communications, 2022, 13, 1577.	5.8	19
4	deepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids. SLAS Discovery, 2022, 27, 175-184.	1.4	10
5	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARÎ´. Nature Communications, 2022, 13, 2665.	5.8	25
6	A rat model to investigate quality of recovery after abdominal surgery. Pain Reports, 2021, 6, e943.	1.4	5
7	Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. Clinical Colorectal Cancer, 2021, 20, 273-278.	1.0	4
8	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 48-56.e2.	1.0	2
9	Suppression of Membranous LRP5 Recycling, Wnt/Î²-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P. Cell Reports, 2020, 32, 108049.	2.9	18
10	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clinical Colorectal Cancer, 2020, 19, 248-255.e6.	1.0	3
11	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	2.9	32
12	Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Research, 2019, 79, 954-969.	0.4	41
13	PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology, 2019, 157, 163-178.	0.6	34
14	Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?. Cancer Prevention Research, 2018, 11, 1-3.	0.7	0
15	The Role of PPAR-Î´ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. International Journal of Molecular Sciences, 2018, 19, 3339.	1.8	113
16	Novel and emerging innate immune therapeutic targets for pancreatic cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 977-981.	1.5	6
17	Oxygenated lipid signaling in tumor-associated macrophagesâ€"focus on colon cancer. Cancer and Metastasis Reviews, 2018, 37, 289-315.	2.7	10
18	ALOX15 as a suppressor of inflammation and cancer: Lost in the link. Prostaglandins and Other Lipid Mediators, 2017, 132, 77-83.	1.0	47

#	Article	IF	Citations
19	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	1.1	25
20	Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2017, 2, e91419.	2.3	58
21	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	1.1	65
22	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget, 2017, 8, 39268-39279.	0.8	69
23	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
24	15â€Lipoxygenaseâ€1 suppression of colitisâ€associated colon cancer through inhibition of the ILâ€6/STAT3 signaling pathway. FASEB Journal, 2015, 29, 2359-2370.	0.2	36
25	Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer. Cancer Prevention Research, 2015, 8, 796-806.	0.7	19
26	Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. International Journal of Radiation Oncology Biology Physics, 2014, 88, 301-305.	0.4	21
27	Potentiation of Colon Cancer Susceptibility in Mice by Colonic Epithelial PPAR-Î´/Î² Overexpression. Journal of the National Cancer Institute, 2014, 106, dju052.	3.0	42
28	Targeting peroxisome proliferator-activated receptor-Î²/Î´ in colon cancer: How to aim?. Biochemical Pharmacology, 2013, 85, 607-611.	2.0	19
29	Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a Web-based tool. Gastrointestinal Endoscopy, 2013, 77, 455-463.	0.5	10
30	Eicosanoid profiling in colon cancer: Emergence of a pattern. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 139-143.	1.0	20
31	Profiling Lipoxygenase Metabolism in Specific Steps of Colorectal Tumorigenesis. Cancer Prevention Research, 2010, 3, 829-838.	0.7	52
32	Targeted Genetic Disruption of Peroxisome Proliferatorâ€“Activated Receptor-Î´ and Colonic Tumorigenesis. Journal of the National Cancer Institute, 2009, 101, 762-767.	3.0	74
33	Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2006, 75, 385-395.	1.0	72
34	The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-Â to induce apoptosis in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9968-9973.	3.3	217
35	Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2001, 19, 4202-4208.	0.8	300
36	Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis, 1999, 20, 1985-1995.	1.3	135